bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2023,
Volume and Issue:
unknown
Published: March 23, 2023
SARS-CoV-2
infection
during
pregnancy
is
associated
with
severe
COVID-19
and
adverse
fetal
outcomes,
but
the
underlying
mechanisms
remain
poorly
understood.
Moreover,
clinical
studies
assessing
therapeutics
against
in
are
limited.
To
address
these
gaps,
we
developed
a
mouse
model
of
pregnancy.
Outbred
CD1
mice
were
infected
at
embryonic
day
(E)
6,
E10,
or
E16
adapted
(maSCV2)
virus.
Outcomes
gestational
age-dependent,
greater
morbidity,
reduced
anti-viral
immunity,
viral
titers,
more
outcomes
occurring
(3rd
trimester-equivalent)
than
either
E6
(1st
E10
(2nd
trimester-equivalent).
assess
efficacy
ritonavir-boosted
nirmatrelvir
(recommended
for
pregnant
individuals
COVID-19),
treated
E16-infected
dams
equivalent
doses
ritonavir.
Treatment
pulmonary
decreased
maternal
prevented
offspring
outcomes.
Our
results
highlight
that
heightened
virus
replication
lungs.
Ritonavir-boosted
mitigated
infection.
These
findings
prompt
need
further
consideration
preclinical
infections.
BMC Pregnancy and Childbirth,
Journal Year:
2023,
Volume and Issue:
23(1)
Published: Aug. 30, 2023
It
is
known
that
SARS-CoV-2
antibodies
from
pregnant
women
with
infection
during
pregnancy
cross
the
placenta
but
duration
and
protective
effect
of
these
in
infants
scarce.This
prospective
study
included
mothers
SARS-COV-2
their
April
2020
to
March
2021.
IgG
spike
protein
were
performed
on
at
birth
two
six
months
follow-up.
Anthropometrical
measures
physical
neurological
examinations
a
clinical
history
symptoms
COVID-19
diagnosis
collected.
Simple
linear
regression
was
compare
categorical
continuous
variables.
To
mother's
infant's
antibody
titers
evolution,
mixed
model
used.
A
predictive
newborn
has
been
established
by
means
simple
stepwise
regression.51
mother-infant
couples
included.
45
(90%)
44
(86.3%)
newborns
had
positive
serology
al
birth.
These
progressively
decreasing
34
(66.7%)
7
(13.7%)
2
6
months,
respectively.
related
mothers'
titers,
moderate
correlation
(Pearson's
coefficient:
0.82,
p
<
0,001).
Fetal/maternal
placental
transference
rate
1.3
(IQR:
0.7-2.2).
The
maternal
delivery
type
(acute,
recent,
or
past
infection)
significantly
infants'
No
other
epidemiological
factors
titers.
Neurodevelopment,
psychomotor
development,
growth
normal
94.2%
third
follow-up
visit.
period.Transplacental
transfer
high
recent
delivery,
decrease
after
first
life.
Infant's
delivery.
Further
studies
are
needed
learn
about
role
infants.
Archives of Disease in Childhood Fetal & Neonatal,
Journal Year:
2023,
Volume and Issue:
108(4), P. 367 - 372
Published: Jan. 6, 2023
Objectives
To
examine
neonates
in
Scotland
aged
0–27
days
with
SARS-CoV-2
infection
confirmed
by
viral
testing;
the
risk
of
neonatal
maternal
and
infant
characteristics;
hospital
admissions
associated
infections.
Design
Population-based
cohort
study.
Setting
population
All
live
births
Scotland,
1
March
2020–31
January
2022.
Results
There
were
141
over
study
period,
giving
an
overall
rate
153
per
100
000
(141/92
009,
0.15%).
Among
infants
born
to
women
around
time
birth,
was
1812
(15/828,
1.8%).
Two-thirds
(92/141,
65.2%)
had
admission
or
(more
commonly)
paediatric
care.
Six
these
babies
(6/92,
6.5%)
admitted
and/or
intensive
care;
however,
none
six
COVID-19
recorded
as
their
main
diagnosis.
no
deaths
among
infection.
Implications
relevance
Confirmed
uncommon
first
23
months
pandemic
Scotland.
Secular
trends
broadly
followed
those
seen
general
population,
although
at
a
lower
level.
Maternal
birth
increased
hospital,
resulting
implications
for
baby,
family
services,
outcomes
generally
good.
Ascertainment
depends
on
extent
testing,
this
is
likely
have
varied
between
groups:
unconfirmed
inevitably
unknown.
Journal of Clinical Investigation,
Journal Year:
2023,
Volume and Issue:
133(20)
Published: Aug. 15, 2023
SARS-CoV-2
infection
during
pregnancy
is
associated
with
severe
COVID-19
and
adverse
fetal
outcomes,
but
the
underlying
mechanisms
remain
poorly
understood.
Moreover,
clinical
studies
assessing
therapeutics
against
in
are
limited.
To
address
these
gaps,
we
developed
a
mouse
model
of
pregnancy.
Outbred
CD1
mice
were
infected
at
embryonic
day
(E)
6,
E10,
or
E16
adapted
(maSCV2)
virus.
Outcomes
gestational
age-dependent,
greater
morbidity,
reduced
anti-viral
immunity,
viral
titers,
impaired
growth
neurodevelopment
occurring
(3rd
trimester-equivalent)
than
either
E6
(1st
E10
(2nd
trimester-equivalent).
assess
efficacy
ritonavir-boosted
nirmatrelvir
(recommended
for
pregnant
individuals
COVID-19),
treated
E16-infected
dams
equivalent
doses
ritonavir.
Treatment
pulmonary
decreased
maternal
prevented
offspring
restriction
neurodevelopmental
impairments.
Our
results
highlight
that
heightened
virus
replication
lungs.
Ritonavir-boosted
mitigated
morbidity
along
after
infection.
These
findings
prompt
need
further
consideration
preclinical
infections.
Frontiers in Audiology and Otology,
Journal Year:
2023,
Volume and Issue:
1
Published: Aug. 11, 2023
Interest
in
hearing
loss
associated
with
COVID-19
has
increased
since
the
pandemic
started.
Early
on
during
spread
of
SARS-CoV-2
across
globe,
reports
smell
and
taste
disorders
secondary
to
emerged,
a
lesser
extent,
sensorineural
also
surfaced.
This
raised
questions
regarding
changes
epidemiology
modifications
otologic
practice
that
have
evolved
response
pandemic.
To
elucidate
these
questions,
we
performed
comprehensive
literature
search,
including
articles
up
November
2022,
using
“COVID
loss”
MEDLINE.
A
total
153
were
included
for
full-text
review
data
extraction.
There
are
several
proposed
mechanisms
through
which
may
contribute
loss—direct
viral
infection,
microthrombi,
or
hemorrhage.
is
growing
repository
case
series
SARS-CoV-2-associated
loss,
variable
quality.
Most
patients
who
experienced
did
so
within
month
most
patients'
symptoms
resolving
2
weeks.
The
body
discussing
does
not
suggest
significant
rise
occurrence
overall
loss.
In
this
ongoing
era,
should
be
approached
same
state-of-the-art
manner
as
before
Frontiers in Pediatrics,
Journal Year:
2024,
Volume and Issue:
12
Published: April 25, 2024
Limited
evidence
exists
on
management
recommendations
for
neonates
born
to
SARS-CoV-2-positive
mothers.
This
study
looked
at
transmission
risk
of
presenting
primary
care
in
a
large
regional
health
system
within
New
York
during
the
early
months
COVID-19
pandemic.
